Plk1 resistance

Author: ycbv

August undefined, 2024

WebbGenetic and pharmacological blockade of PLK1 significantly increases the sensitivity to oxaliplatin in vitro and in vivo. Mechanistically, transcriptomic profiling analysis reveals … Webb1 dec. 2024 · Several PLK1 mutations have been already described in resistant cells to PLK1 inhibitors. These data supported our research in this regard, and evidenced the …

Targeting PI3K and PLK1 to Overcome Ibrutinib-Venetoclax …

Webb17 feb. 2024 · PLK1 is characterized by a C-terminal Polo-Box domain, which mediates subcellular localization and protein interactions and regulates the N-terminal … WebbWhile studies have indicated that the use of PLK1 inhibition may overcome drug resistance in chemotherapy [31,32,33], other research has aimed to enhance the efficacy of standard therapy through PLK1i-based combinations, such as in ovarian cancer with CCNE1 amplification, where the PLK1 inhibitor BI6727 in combination can potentiate the effect … jeremias 33 15

PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis

Webb17 apr. 2024 · PLK1 is highly expressed in TNBC tissue and inhibition of ... Broman MM, Carlock C, Chen L, et al. Targeting Plk1 to enhance efficacy of olaparib in castration-resistant prostate cancer. Mol ... Webb28 okt. 2024 · In the present article we investigated the potential mechanism of acquired resistance to BETi in TNBC and, through the identification of PLK1 as a target to … Webb7 dec. 2024 · Inhibition of PLK1 abolished the oncogenic function of HN1L and enhanced the antitumor effect of chemotherapy, which suggests a potential therapeutic strategy … jeremias 33 14-16

Plk1 regulates MEK1/2 and proliferation in airway smooth muscle …

PLK1 Is Transcriptionally Activated by NF-κB during Cell …

Webb12 juli 2024 · PLK1 inhibition holds potentials for cancer therapy while it is challenging for the development of effective PLK1 inhibitors in clinical cancer therapy. The in-depth … Webb13 nov. 2024 · Copanlisib at low dosage of 6 mg/kg/2d significantly inhibited in vivo tumor growth of an ibrutinib-venetoclax dual-resistant PDX model. PLK1, a central player in regulating G2/M transition, acts upstream of PI3K/AKT signaling via phosphorylating PTEN to cause a tumor-promoting metabolic state. jeremias 33 11Webb13 aug. 2024 · PLK1 inhibition results in tumour shrinkage in highly proliferating CCND1-driven PDX, including different RB-positive PDX with acquired palbociclib resistance. … jeremias 33 3-4

"Webb) or α-casein for Plk1 for 20 min at 30 °C. ABL kinase activity was assessed using 10 ng of WT ABL or imatinib-resistant ABL mutants (Invitrogen) and the peptide substrate ABLtide for 20 min at 30 °C in the presence of 100 μ m [γ- 32 P]ATP and the indicated concentration of imatinib or VX-680. " - Plk1 resistance

Plk1 resistance

National Center for Biotechnology Information

Webb28 okt. 2024 · JQ1-resistant cells orthotopically xenografted into the mammary fat pad of mice led to tumours that retained JQ1-resistance. Administration of the PLK1 inhibitor volasertib resulted in tumour regression. These findings open avenues to explore the future use of PLK1 inhibitors in the clinical setting of BETi-resistant patients. Webb1 feb. 2024 · PLK1-based combination therapies have shown increased apoptosis, disrupted cell cycle, and potential to overcome resistance in cancer cells/tissues over …

Did you know?

Webb5 feb. 2024 · Polo-like kinase 1 (Plk1) expression is inversely correlated with survival advantages in many cancers. However, molecular mechanisms that underlie Plk1 … WebbNational Center for Biotechnology Information

WebbAt Boundless Bio, we are focused on discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence. I ... WebbWe identified Polo-like kinase 1 (PLK1), a mitotic kinase, as a resistance mediator whose genomic as well as pharmacological inhibition restored drug sensitivity. Both acquired …

Webb4 sep. 2008 · Here we show that in human cells PLK1 activation occurs several hours before entry into mitosis, and requires aurora A (AURKA, also known as STK6) … Webb14 apr. 2024 · When overexpressed in head and neck cancer cells, it causes the cells to divide abnormally and at a faster rate, leading to the accumulation of more cancer cells. Using data from The Cancer Genome ...

Webb11 juli 2003 · Plk1 (Polo-like kinase 1), an evolutionarily conserved serine/threonine kinase, is crucially involved in multiple events during the M phase. Here we have identified a …

Webb13 nov. 2024 · PLK1, a central player in regulating G2/M transition, acts upstream of PI3K/AKT signaling via phosphorylating PTEN to cause a tumor-promoting metabolic … lamar jackson jersey ebayWebb23 sep. 2024 · Thus, PLK1 inhibition appears to be a promising therapeutic strategy 5, 22, although the mechanism of PLK1 upregulation by LHBs remains unclear. Finally, validating the clinical significance of their experimental results, the authors show an association between LHBs expression and hepatocyte aneuploidy in liver sections of patients with … lamar jackson daughterWebbPDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy This work identifies … jeremias 33 33Webb27 feb. 2024 · Rigosertib (ON-01910.Na) is a small-molecule member of the novel synthetic benzyl-styryl-sulfonate family. It is currently in phase III clinical trials for several myelodysplastic syndromes and leukemias and is therefore close to clinical translation. The clinical progress of rigosertib has been hampered by a lack of understanding of its … jeremias 33:3Webbwww.ncbi.nlm.nih.gov lamar jackson injury status todayWebb14 apr. 2024 · CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer Clinical Cancer Research American Association for Cancer … jeremias 33 3Webb5 feb. 2024 · 1 1 A novel mechanism of H IF 2-dependent P L K 1-mediated metastasis and drug resistance of 2 clear cell Renal Cell Carcinoma 3 4 5 Maeva Dufies 1*, Annelies Verbiest 2,3, Lindsay S Cooley 4, Papa Diogop Ndiaye 5, Julien Viotti 6, 6 Xingkang He 7, Nicolas Nottet 8, Wilfried Souleyreau 4, Anais Hagege 5, Stephanie Torrino 9, Julien lamar jackson lowest passing yards